UNSPSC 51313801: Fexofenadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6582LOH6V, chemically known as 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid but generally known as fexofenadine, which bears US NIH Compound Identifier 3348. European Medicines Agency schedules Fexofenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13883MIG.

UNSPSC 51313801 Fexofenadine is a Commodity code representing a single pharmaceutical product line, yet recent state and local opportunities tagged under this code show minimal direct activity for fexofenadine itself. Instead, the three recent solicitations address pharmaceutical supply and distribution more broadly—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. The code appears to function as a catch-all pharmaceutical tag in some state and local procurement systems rather than driving targeted procurement for this specific antihistamine. When fexofenadine procurement does occur, it typically flows through cooperative purchasing frameworks and multi-vendor pharmaceutical supply agreements rather than standalone solicitations. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP). These entities manage pharmaceutical procurement through authorized wholesalers and manufacturers rather than direct end-user purchases, reflecting standard pharmacy benefit and supply-chain models in state and local government.

Recent activity centers on Florida, Texas, and the Minnesota-Oregon multistate region. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without formal competitive bidding parameters. Minnesota MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The MMCAP procurement drives significant volume through cooperative purchasing and requires vendor compliance with cGMP, DSCSA, and FDA regulations, with contract administration fees of 3 percent. Fexofenadine-specific procurement opportunities appear limited in the recent record; pursuit under this code should focus on cooperative pharmaceutical supply agreements and multistate purchasing vehicles rather than standalone product solicitations.